All asymptomatic adults should now begin screening for prediabetes and type 2 diabetes at age 35 , down from the previous recommendation of age 45.
For patients with established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease (CKD), SGLT2 inhibitors or GLP-1 receptor agonists are recommended independent of A1C or metformin use. american diabetes association guidelines 2022 pdf download
For clinicians and patients seeking the official documentation, the provides the complete clinical framework for managing all types of diabetes. 1. Key Screening & Diagnosis Updates All asymptomatic adults should now begin screening for
The ADA now emphasizes early combination therapy (e.g., adding a GLP-1 RA to insulin) rather than simply increasing insulin doses to achieve glycemic targets. aggressive management of comorbidities
Weight loss is recognized as a primary goal of therapy, with GLP-1 RAs and SGLT2 inhibitors favored for their weight-lowering benefits. 3. Chronic Kidney Disease (CKD) Management
The represents a pivotal shift toward earlier screening, aggressive management of comorbidities, and the integration of advanced technology in daily care.
If results are normal, testing should be repeated at least every 3 years . 2. Pharmacologic Advances for Type 2 Diabetes